MedTrace Logo

Molecular Study of the Maternal-fetal Interface in Preeclampsia.

NCT06232668 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2084

Last updated 2026-04-13

No results posted yet for this study

Summary

Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization that prevents the establishment of a functional maternal-fetal interface has been evidenced. The main objective of this study is to identify molecular markers or aberrant maternal-fetal cell types that can be detected early in the development of the disease in maternal-fetal interface tissue (chorionic villi + decidua) collected during gestational weeks 9 to 15. Maternal-fetal interface biopsy will be collected from women who have a recommendation for aneuploidy testing. The remaining fragment will be used for this study.

Conditions

Interventions

PROCEDURE

Maternal-fetal interface biopsy and peripheral blood collection in cases group

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.

PROCEDURE

Maternal-fetal interface biopsy and peripheral blood collection in control group

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.

Sponsors & Collaborators

  • Carlos Simon Foundation

    lead OTHER

Principal Investigators

  • Tamara Garrido, PhD · Fundación Carlos Simon para la investigación en salud de la mujer

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-20
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06232668 on ClinicalTrials.gov